Nutra Pharma begins Indian registration process for Nyloxin pain drugs; seeks local partner

US biotech firm Nutra Pharma Corp (OTC.BB:NPHC), which is developing treatments for adrenomyeloneuropathy, HIV, multiple sclerosis and pain, said yesterday that it has begun the drug registration process in India for its Nyloxin line of pain relievers.

According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.

"India represents one of the more significant international market opportunities for Nyloxin," commented Rik Deitsch, chairman and chief executive of Nutra Pharma. "With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India presents a potentially significant customer base for Nyloxin," he added.